Monalizumab
Подписчиков: 0, рейтинг: 0
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | NKG2A |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.
Mechanism of action
Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpoint inhibitor.